Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with SIB-IMRT for Locally Advanced Rectal Cancer
NCT06017583Phase 3Recruiting
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in rectal cancer (2 arms). Primary endpoint: Complete Response Rate at 18 weeks. Started Sep 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06017583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06017583.